We applied scRNA-seq to measure the transcriptomes of a total of 26,979 single cells obtained from the A375 melanoma cell line grown under 4 different conditions: untreated/sensitive (S), treatment-resistant to BRAF inhibitor vemurafenib alone (RV) or treatment-resistant to a combination of vemurafenib with the MEK1/2 inhibitors cobimetinib (RVC) or trametinib (RVT) (Figure 1). Here, BRAF is linked to melanoma.